Integral develops technologies aimed at addressing neurological and psychiatric disorders through advanced neuroengineering. Their first product, an implanted deep-brain interface, is designed to serve severely affected patients by enabling sophisticated recording and modulation of neural activity, alongside real-time symptom monitoring. This device marks a significant step forward in both the treatment of brain disorders and the understanding of their underlying biological mechanisms. Integral operates with a strong emphasis on ambitious engineering and swift execution, prioritizing the needs of patients as they expand their portfolio of innovative treatments. The company’s leadership includes professionals with deep expertise in medtech and neuroscience, fostering a collaborative environment focused on impactful outcomes in the field of neurotechnology.